Thought Leadership
FDA Regulation of HCT/Ps – Impact of New Guidances on Manufacturers and Users
August 2015
Stacie Ropka and Chad Landmon
GxP Lifeline

Axinn Counsel Stacie Ropka and Partner Chad Landmon authored, "FDA Regulation of  CT/Ps – Impact of New Guidances on Manufacturers and Users," which was published in MasterControl's GxP Lifeline newsletter.

Click here to read the article. 

By using the Axinn, Veltrop & Harkrider LLP website with cookies enabled on your browser, you agree to our use of cookies during your browsing experience. Learn more about our privacy policy.